1	Cetus	_	NNP	_	_	3	SBJ	_	_
2	Corp.	_	NNP	_	_	1	POSTHON	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	government	_	NN	_	_	8	SBJ	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Spain	_	NNP	_	_	6	PMOD	_	_
8	approved	_	VBD	_	_	3	OBJ	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	marketing	_	NN	_	_	8	OBJ	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	its	_	PRP$	_	_	15	NMOD	_	_
13	Proleukin	_	NNP	_	_	15	NMOD	_	_
14	interleukin-2	_	NN	_	_	15	NMOD	_	_
15	drug	_	NN	_	_	11	PMOD	_	_
16	to	_	TO	_	_	15	NMOD	_	_
17	treat	_	VB	_	_	16	IM	_	_
18	kidney	_	NN	_	_	19	NMOD	_	_
19	cancer	_	NN	_	_	17	OBJ	_	_
20	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	biotechnology	_	NN	_	_	3	NMOD	_	_
3	concern	_	NN	_	_	4	SBJ	_	_
4	said	_	VBD	_	_	0	ROOT	_	_
5	Spanish	_	JJ	_	_	6	NMOD	_	_
6	authorities	_	NNS	_	_	7	SBJ	_	_
7	must	_	MD	_	_	4	OBJ	_	_
8	still	_	RB	_	_	7	ADV	_	_
9	clear	_	VB	_	_	7	VC	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	price	_	NN	_	_	9	OBJ	_	_
12	for	_	IN	_	_	11	NMOD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	treatment	_	NN	_	_	12	PMOD	_	_
15	,	_	,	_	_	7	P	_	_
16	but	_	CC	_	_	7	COORD	_	_
17	that	_	IN	_	_	16	CONJ	_	_
18	it	_	PRP	_	_	19	SBJ	_	_
19	expects	_	VBZ	_	_	17	SUB	_	_
20	to	_	TO	_	_	19	OPRD	_	_
21	receive	_	VB	_	_	20	IM	_	_
22	such	_	JJ	_	_	23	NMOD	_	_
23	approval	_	NN	_	_	21	OBJ	_	_
24	by	_	IN	_	_	21	TMP	_	_
25	year	_	NN	_	_	26	NMOD	_	_
26	end	_	NN	_	_	24	PMOD	_	_
27	.	_	.	_	_	4	P	_	_

1	Four	_	CD	_	_	3	NMOD	_	_
2	other	_	JJ	_	_	3	NMOD	_	_
3	countries	_	NNS	_	_	6	SBJ	_	_
4	in	_	IN	_	_	3	LOC	_	_
5	Europe	_	NNP	_	_	4	PMOD	_	_
6	have	_	VBP	_	_	0	ROOT	_	_
7	approved	_	VBN	_	_	6	VC	_	_
8	Proleukin	_	NNP	_	_	7	OBJ	_	_
9	in	_	IN	_	_	7	TMP	_	_
10	recent	_	JJ	_	_	11	NMOD	_	_
11	months	_	NNS	_	_	9	PMOD	_	_
12	.	_	.	_	_	6	P	_	_

1	Cetus	_	NNP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	currently	_	RB	_	_	2	TMP	_	_
4	trying	_	VBG	_	_	2	VC	_	_
5	to	_	TO	_	_	4	OPRD	_	_
6	obtain	_	VB	_	_	5	IM	_	_
7	federal	_	JJ	_	_	9	NMOD	_	_
8	regulatory	_	JJ	_	_	9	NMOD	_	_
9	clearance	_	NN	_	_	6	OBJ	_	_
10	for	_	IN	_	_	9	NMOD	_	_
11	U.S.	_	NNP	_	_	12	NMOD	_	_
12	distribution	_	NN	_	_	10	PMOD	_	_
13	.	_	.	_	_	2	P	_	_

